Published in Antimicrob Agents Chemother on September 01, 1995
Multiple-drug resistant enterococci: the nature of the problem and an agenda for the future. Emerg Infect Dis (1998) 4.84
DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc Natl Acad Sci U S A (1997) 2.99
Killing of Staphylococcus aureus by C-8-methoxy fluoroquinolones. Antimicrob Agents Chemother (1998) 1.86
Survival of Enterococcus faecalis in mouse peritoneal macrophages. Infect Immun (1999) 1.25
In vitro activities of clinafloxacin against contemporary clinical bacterial isolates from 10 North American centers. Antimicrob Agents Chemother (1998) 1.17
In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. Antimicrob Agents Chemother (2007) 1.13
Comparative activities of clinafloxacin against gram-positive and -negative bacteria. Antimicrob Agents Chemother (1998) 1.03
Intravenous mouse infection model for studying the pathology of Enterococcus faecalis infections. Infect Immun (2003) 0.96
Activities of clinafloxacin, alone and in combination with other compounds, against 45 gram-positive and -negative organisms for which clinafloxacin MICs are high. Antimicrob Agents Chemother (1999) 0.94
In vivo therapeutic efficacies of PD 138312 and PD 140248, two novel fluoronaphthyridines with outstanding gram-positive potency. Antimicrob Agents Chemother (1995) 0.75
Pharmacokinetics of cefazolin compared with four other cephalosporins. J Infect Dis (1973) 3.91
Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates. Antimicrob Agents Chemother (1991) 2.26
Multiply-resistant Enterococcus faecium. The nosocomial pathogen of the 1990s. JAMA (1992) 2.15
The Garrod Lecture. The enterococcus: a classic example of the impact of antimicrobial resistance on therapeutic options. J Antimicrob Chemother (1991) 1.90
Beta-lactamase-producing enterococci. Antimicrob Agents Chemother (1992) 1.85
In vitro antibacterial activities of PD 131628, a new 1,8-naphthyridine anti-infective agent. Antimicrob Agents Chemother (1991) 1.67
Comparative in vitro activity of PD 127391, a new fluoroquinolone agent, against susceptible and resistant clinical isolates of gram-positive cocci. Antimicrob Agents Chemother (1992) 1.52
Increasing resistance of enterococci to ciprofloxacin. Antimicrob Agents Chemother (1992) 1.40
In vitro antibacterial activities of the fluoroquinolones PD 117596, PD 124816, and PD 127391. Diagn Microbiol Infect Dis (1991) 1.31
Antimicrobial activity evaluations of two new quinolones, PD127391 (CI-960 and AM-1091) and PD131628. Diagn Microbiol Infect Dis (1992) 1.31
Funding crunch hobbles antibiotic resistance research. Science (1994) 0.93
Activity of clinafloxacin against multidrug-resistant Enterococcus faecium. Antimicrob Agents Chemother (1994) 0.93
In vitro antibacterial activities of PD 138312 and PD 140248, new fluoronaphthyridines with outstanding gram-positive potency. Antimicrob Agents Chemother (1993) 0.92
Bacterial resistance to the cyclic glycopeptides. Trends Microbiol (1994) 0.83
Increasing prevalence of resistance to ampicillin, penicillin and vancomycin of enterococci isolated from blood cultures during 1990-1991. J Antimicrob Chemother (1993) 0.82
Inhibition of the Staphylococcus aureus NADPH-dependent enoyl-acyl carrier protein reductase by triclosan and hexachlorophene. J Biol Chem (2000) 1.93
In vitro antibacterial activities of PD 131628, a new 1,8-naphthyridine anti-infective agent. Antimicrob Agents Chemother (1991) 1.67
The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents. J Med Chem (1995) 1.49
Structure-activity relationships of quinolone agents against mycobacteria: effect of structural modifications at the 8 position. Antimicrob Agents Chemother (1996) 1.46
In vitro antibacterial activities of the fluoroquinolones PD 117596, PD 124816, and PD 127391. Diagn Microbiol Infect Dis (1991) 1.31
Bacterial eradication by clinafloxacin, CI-990, and ciprofloxacin employing MBC test, in-vitro time-kill and in-vivo time-kill studies. J Antimicrob Chemother (1998) 1.30
In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin. J Antimicrob Chemother (1997) 1.27
In vitro activity of sparfloxacin (CI-978, AT-4140, and PD 131501). A quinolone with high activity against gram-positive bacteria. Diagn Microbiol Infect Dis (1992) 0.99
Fluoroquinolones: relationships between structural variations, mammalian cell cytotoxicity, and antimicrobial activity. J Med Chem (1992) 0.96
Activity of clinafloxacin, trovafloxacin, quinupristin/dalfopristin, and other antimicrobial agents versus Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Diagn Microbiol Infect Dis (1999) 0.95
In vitro antibacterial activities of PD 138312 and PD 140248, new fluoronaphthyridines with outstanding gram-positive potency. Antimicrob Agents Chemother (1993) 0.92
In-vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum to clinafloxacin, PD 131628, ciprofloxacin and comparator drugs. J Antimicrob Chemother (1997) 0.88
In vitro evaluation of cefdinir (FK482), a new oral cephalosporin with enhanced antistaphylococcal activity and beta-lactamase stability. Diagn Microbiol Infect Dis (1994) 0.87
Efficacy of quinolones in preventing Staphylococcus aureus-induced abscess in mice. J Antimicrob Chemother (1995) 0.83
Nasal toxicity of CI-959, a novel anti-inflammatory drug, in Wistar rats and Beagle dogs. Toxicol Pathol (1999) 0.79
Effect of l-dopa or bromocriptine on feeding and motor behavior of rats with lesions in the globus pallidus. Physiol Behav (1984) 0.78
Toxicological comparison of a muscarinic agonist given to rats by gavage or in the diet. Food Chem Toxicol (1996) 0.76
Sparfloxacin worldwide in vitro literature: isolate data available through 1994. Diagn Microbiol Infect Dis (1996) 0.75
Carcinogenicity of the anticancer topoisomerase inhibitor, amsacrine, in Wistar rats. Fundam Appl Toxicol (1996) 0.75
Recurrent colonic dilatation in a cynomolgus macaque: similarity to idiopathic colonic pseudo-obstruction in humans. Lab Anim Sci (1992) 0.75
Leucovorin protection against repeated daily dose toxicity of trimetrexate in rats. Fundam Appl Toxicol (1993) 0.75
In vivo therapeutic efficacy of cefdinir (FK482), a new oral cephalosporin, against Staphylococcus aureus and Haemophilus influenzae in mouse infection models. Diagn Microbiol Infect Dis (1994) 0.75
College students' use of emergency medical services. J Am Coll Health (1990) 0.75